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Cross-sectional magnetic resonance imaging (MRI) suggests that Parkinson’s disease
(PD) is associated with changes in cerebral tissue volume, diffusion tensor imaging metrics,
and perfusion values. Here, we performed a longitudinal multimodal MRI study—including
structural, diffusion tensor imaging (DTI), and perfusion MRI—to investigate progressive
brain changes over one year in a group of older PD patients at a moderate stage of disease.
Methods
Twenty-three non-demented PD (mean age (SD) = 69.5 (6.4) years, disease duration (SD)
= 5.6 (4.3) years) and 23 matched control participants (mean age: 70.6 (6.8)) completed
extensive neuropsychological and clinical assessment, and multimodal 3T MRI scanning at
baseline and one year later. We used a voxel-based approach to assess change over time
and group-by-time interactions for cerebral structural and perfusion metrics.
Results
Compared to controls, in PD participants there was localized grey matter atrophy over time
in bilateral inferior and right middle temporal, and left orbito-frontal cortices. Using a voxel-
based approach that focused on the centers of principal white matter tracts, the PD and con-
trol cohorts exhibited similar levels of change in DTI metrics. There was no significant
change in perfusion, cognitive, or motor severity measures.
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Conclusions
In a cohort of older, non-demented PD participants, macrostructural MRI detected atrophy
in the PD group compared with the control group in temporal and orbito-frontal cortices.
Changes in diffusion MRI along principal white matter tracts over one year were found, but
this was not differentially affected by PD.
Introduction
Detailed information on progressive brain changes is needed to help assess novel Parkinson’s
disease (PD) modifying therapies. Progression based solely on clinical assessments is valuable,
but unlike objective biomarkers, clinical measures cannot differentiate between symptomatic
relief and neuroprotection. Structural MRI has provided biomarkers in neurodegenerative dis-
eases such as Alzheimer’s disease (AD) [1], while cross sectional MRI studies in PD have iden-
tified robust brain differences associated with both clinical and cognitive measures [2–8]. Serial
imaging predicts progression in progressive neurodegenerative diseases [9–11], and therefore
may also track progression in PD.
Studies have reported progressive brain atrophy in PD over 1–4 years, but it is uncertain
whether atrophy is significantly greater in PD than that seen in healthy ageing subjects [12–
23]. Moreover, the value of serial diffusion [24] and perfusion MRI is relatively unexplored in
the context of PD progression. Here, we performed a one year longitudinal multimodal MR
imaging study—including structural, diffusion, and perfusion MRI—to investigate progressive
brain changes over one year in a group of 23 non-demented, older, PD patients at a moderate
stage of disease and 23 healthy control volunteers. We chose the relatively short one-year inter-
val for reasons of applicability in research and clinical practice. Large-scale clinical trials exam-
ining potential therapies for neuroprotection are expensive and the establishment of an
objective marker that can show clinically meaningful disease progression—and lack of progres-




A convenience sample of 27 participants meeting the UK Parkinson’s Disease Society’s criteria
for idiopathic PD [25], were recruited from volunteers at the Movement Disorders Clinic at the
New Zealand Brain Research Institute, Christchurch, New Zealand. Exclusion criteria at base-
line included atypical parkinsonian disorder; history of other neurological conditions such as
moderate-severe head injury, stroke, dementia; and major psychiatric or medical illness (previ-
ous six months). Twenty-three healthy controls, free from a history of major neurological or
psychiatric disorders were also recruited, matched to the PD group by mean age and education
years, and sex ratio.
From December 2010 –August 2013, eligible subjects were invited to undertake neuropsy-
chological testing, clinical assessment, and MRI scanning at baseline (Y0) and one year (± 1
month) later (Y1). All MRI scans at Y0 and Y1 were screened by a consultant neuroradiologist
(RJK) to exclude significant non-PD cerebral pathology. At Y1, one PD patient was unable to
participate due to a non-PD illness, two patients declined to participate at follow up, and one
patient was excluded due to new left occipitotemporal and right thalamic infarcts. After visual
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inspection, excess motion necessitated removal of T1-weighted images from two PD patients
assessed as showing normal cognition (PDN) at both timepoints and the perfusion scan from
one patient who was PDN at Y0 but converted to dementia at Y1). No diffusion datasets were
excluded. Hence there were 23 healthy controls for all imaging analyses, but a different number
of PD participants across imaging modalities: 21 for grey matter, 23 for diffusion, and 20 for
perfusion MRI (see Table 1 for characteristics of the final sample). All subjects gave written
consent, with additional consent from a significant other when appropriate. The study was
approved by the regional Ethics Committee of the New Zealand Ministry of Health (No. URB/
09/08/037).
Diagnostic Criteria and Assessment (Y0 and Y1)
Motor function was assessed using the Movement Disorders Society Unified Parkinson’s Dis-
ease Rating Scale (MDS-UPDRS: part 3) [26] and cognition by comprehensive neuropsycho-
logical testing [4, 27, 28]. PD patients were classified as either cognitively normal (PDN,
n = 20), with mild cognitive impairment (PD-MCI, n = 4, MDS Task force level II criteria
[29]), or dementia [30]. MCI cases had unimpaired functional activities of daily living, as veri-
fied by interview with a significant other, but scored 1.5 SD or more below normative data on
at least two measures within at least one of five MDS cognitive domains (executive function;
attention, working memory and processing speed; learning and memory; visuospatial/visuo-
perceptual function; and language; see S1 Table for a list of the tests used). Cognitive domain
scores were derived from averaged standardized scores from constituent domain tests; global
cognition was expressed by averaging four domain z-scores (language excluded due to low vari-
ance) to form a single mean cognitive z-score. At Y0, two control participants met criteria for
MCI, however at Y1 both were classified as having normal cognition.
At Y0, four PD participants were drug-naïve with respect to anti-parkinsonian medication;
three remained drug-naïve at Y1. In all other PD individuals, motor, cognitive, and MRI assess-
ments were performed on medication, with no change to their usual drug regimen. Daily dopa-
minergic medications were standardized into a levodopa equivalent dose (LED) [31].
Magnetic Resonance Imaging acquisition (Y0 and Y1)
Imaging was conducted on a 3T General Electric HDxt scanner (GE Healthcare, Waukesha,
USA) with an eight-channel head coil.
Table 1. Demographic and clinical data in PD and control groups at baseline.
Control PD
n 23 23
Age 70.6 (6.8) 69.5 (6.4)
Male:female 16:7 17:6
Education (years) 13.5 (2.3) 13.0 (3.0)
N:MCI:dementia Y0 21:2:0 19:4:0
N:MCI:dementia Y1 23:0:0 17:5:1
Disease duration from diagnosis (years) - 5.6 (4.3)
Time between scans (years) 1.0 (0.07) 0.98 (0.12)
Data presented as ratios or mean (SD). PD = Parkinson’s disease; Y0 = baseline; Y1 = follow up;
N = cognition in the normal range; MCI = mild cognitive impairment.
doi:10.1371/journal.pone.0143923.t001
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Conventional structural. Volumetric T1-weighted (inversion-prepared spoiled gradient
recalled echo (SPGR), TE/TR = 2.8/6.6 ms, TI = 400 ms, flip angle = 15 deg, acquisition
matrix = 256×256×170, FOV = 250 mm, slice thickness = 1 mm) and clinical T2 and T2
FLAIR images were collected.
Diffusion tensor imaging. A 2D diffusion-weighted, spin echo, echo planar imaging
sequence was used to measure microstructural integrity, with diffusion weighting in 28 uni-
formly distributed directions (b = 1000 s/mm2) and 4 acquisitions without diffusion weighting
(b = 0 s/mm2): TE/TR = 86.4/13000 ms, flip angle = 90 deg, acquisition matrix = 128×128×48,
reconstruction matrix = 256×256×48, FOV = 240 mm, slice thickness = 3 mm, reconstructed
voxel size = 1.07×1.07×3 mm3, NEX = 1, ungated.
Arterial spin labelling. A stack of spiral, fast spin echo acquired images were prepared
with pseudo-continuous arterial spin labelling and background suppression to measure whole
brain perfusion quantitatively [32]: TR = 6 s, echo spacing = 9.2 ms, post-labelling
delay = 1.525 s, labelling duration = 1.5 s, eight interleaved spiral arms with 512 samples at 62.5
kHz bandwidth and 30 phase encoded 5mm thick slices, NEX = 5, units: ml/100 g/min). Partic-
ipants were asked to close their eyes.
Structural MRI Preprocessing
For each participant, Y0 and Y1 structural (SPGR) images were aligned to a subject-specific
midpoint-space between the two scans using the longitudinal registration utility in SPM12b
(v5581, http://www.fil.ion.ucl.ac.uk/spm/), running in Matlab R2010a, using default values [33].
The mid-point average image for each individual was then segmented and grey matter (GM)
atrophy rate images produced by multiplying the native space GM segments (both Y0 and Y1)
by the Jacobian rate. We then ran DARTEL (existing template) using the template provided
with the VBM8 toolbox (in MNI space, http://dbm.neuro.uni-jena.de/vbm/). GM atrophy rate
images, as well as the mid-space average GM segments, were then normalized using the DAR-
TEL flow fields, modulated, and smoothed (8 mm FWHM). A GMmask was created by averag-
ing all normalized, modulated GM segments, thresholding at 0.2 and smoothing (8 mm). In
addition, default parameters were used to estimate percent brain volume change over one year
using SIENA (FSL v5.0.2, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/, note: there was no correction for
intracranial volume as SIENA calculates percent volume change relative to baseline) [34].
DTI preprocessing
Preprocessing and analyses were performed in FSL per Engvig et al. [35]. At each timepoint, this
included motion- and eddy current distortion-correction; rotation of the b matrix accordingly;
motion quantification via root mean square deviation between each pair of realigned diffusion
images and averaging over all pairs to create a single, ‘relative’motion metric; brain extraction;
and fitting a diffusion tensor to produce fractional anisotropy (FA), mean diffusivity (MD), axial
diffusivity (L1, the principal diffusion eigenvalue), and radial diffusivity (RD, the mean of the sec-
ond and third eigenvalues) images. FA images for Y0 and Y1 were linearly registered (FLIRT),
resampled into the space halfway between the two, and averaged to create a midpoint-space sub-
ject average FA. This was then entered into a tract-based spatial statistics (TBSS) analysis to cre-
ate the group-wise FA skeleton (thinned at FA>0.27), representing the centers of all tracts
common to all participants [36]. Midpoint-space registered FA images (Y0 and Y1) were
smoothed (sigma = 2) to reduce residual misalignment between Y0 and Y1 images, and projected
onto the skeleton to create separate FA skeletons at Y0 and Y1. Using the transforms derived
from the FA procedure, we created separate MD, L1, and RD skeletons at each timepoint. Lastly,
we created average and difference FA, MD, L1, and RD skeletonized images for each individual.
One Year MRI Follow Up in PD
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ASL preprocessing
At each timepoint, quantified cerebral blood perfusion images were co-registered to the struc-
tural image. Structural images were brain extracted using BET (in FSL), and the resulting brain
mask was used to exclude non-brain tissue in the ASL images. Deformation fields mapping
either Y0 or Y1 to the mid-point average were combined with the DARTEL flow fields to nor-
malize the quantified perfusion image at each timepoint. We then created average perfusion
and difference images for each individual, which were smoothed (10 mm).
Statistical Analyses
Clinical, cognitive, and global MRI measures were compared across time and group using lin-
ear mixed-effects models with the nlme package in R (v3.0.0). Global MRI metrics included (1)
percent brain volume change (SIENA), and at each timepoint, (2) DTI metrics averaged across
the white matter skeleton, and (3) average grey matter perfusion extracted from the GMmask.
Baseline age, sex, education and time between scans were included in all models. Relative
motion was included in the DTI models only.
Voxel-wise statistical analysis
All voxel-wise comparisons were performed using a permutation-based inference tool for non-
parametric thresholding (FSL’s “randomise”) [37]. Group, time, and group-by-time interac-
tions were investigated for each of 6 imaging measures (GM volume, FA, MD, L1, RD, and per-
fusion). The group effect (controls vs PD) was tested by investigating an average image for
each individual (two sample t-test); difference images were used to investigate time effects in
each group separately (one sample t-test) and group-by-time interactions (via two sample t-
test of difference images). For all comparisons, age at Y0, sex, and years of education were
included as covariates. For perfusion and DTI comparisons, time between scans was entered as
a covariate (this was incorporated into the preprocessing of GM volume); de-meaned baseline
scans were included as voxel-wise covariates to account for potential baseline differences. Rela-
tive motion was entered as an additional covariate in the DTI models (average relative motion
for the group comparison and difference in relative motion for time and group-by-time com-
parisons). For each contrast, the null distribution was generated over 5000 permutations and
the alpha level set at p<0.05, corrected for multiple comparisons (family-wise error correction
using threshold-free cluster-enhancement (TFCE)) [38].
Results
By Y1, two PDN individuals met a worse cognitive criterion, one to PD-MCI and one to PDD.
The two controls who met criteria for MCI at baseline reverted to the cognitively normal cate-
gory by Y1.
Table 2 summarizes clinical and cognitive data at Y0 and Y1, while Table 3 presents global
MRI metrics at both timepoints. At baseline, we identified cognitive impairment in PD rela-
tive to controls (global cognitive z-scores and all individual domain scores except Language
were significantly lower, although MoCA scores were not). Relative motion during the DTI
scan was not significantly different between the groups. Furthermore, there were no signifi-
cant effects of time or group-by-time interactions upon cognitive z-score, the five cognitive
domain scores, MoCA, or relative motion, and no significant change in UPDRS III or LED
(Tables 2 and 3).
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Global MRI metrics
Both PD (mean [95% CI], -0.71% [-0.93 –-0.49]) and control groups (-0.48% [-0.70 –-0.25])
showed significant loss of brain tissue over one year (Fig 1A), but this was not significantly dif-
ferent between the groups (Table 3). There were no significant effects of time or group-by-time
interactions upon FA (Fig 1B), MD, L1, or RD averaged across the white matter skeleton, or
average GM perfusion (Fig 1C and Table 3).
Voxel-wise results
Group effects: There were no significant differences in GM volume or DTI metrics between
groups, but there was lower cerebral perfusion in localized medial posterior parietal areas and
right middle temporal gyrus in PD relative to controls (data not shown).
Time effects: In terms of changes across time, irrespective of group, we identified wide-
spread GM atrophy occurring over the one-year period (Fig 2A). FA showed widespread
reduction in numerous principal white matter tracts, specifically in genu, body, and splenium
of corpus callosum, cingulum bundles, superior corona radiata, and the posterior sections of
multiple fasciculi (Fig 2B), while MD, L1, and RD exhibited significant, yet more restricted
increases (Fig 2C–2E). We identified no significant change in cerebral perfusion.
Group-by-time interactions: The PD group exhibited significantly increased GM atrophy
rate (faster loss of tissue) relative to controls in bilateral inferior and right middle temporal
Table 2. Cognitive and clinical metrics at baseline and follow up.
Control group PD group PD vs. Controls
Baseline Change after 12
months
Baseline Change after 12
months






















































































- - 32.6 [26.8–38.4] -1.9 [-6.1–2.2],
p = 0.3
- -
LED (mg/day) - - 609 [410–809] 69 [–15–152],
p = 0.1
- -
MoCA = Montreal Cognitive Assessment, PD = Parkinson’s disease, UPDRS = Unified Parkinson’s Disease Rating Scale part 3.
doi:10.1371/journal.pone.0143923.t002
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Table 3. Global MRI metrics at baseline and follow up.
Control group PD group PD vs. Controls
Baseline Change after 12
months
Baseline Change after 12
months
Baseline difference Relative change
after 12 months
Global MRI Measures Mean [95%
CI]
Mean [95%CI] Mean [95%
CI]
Mean [95%CI] Mean [95%CI] Mean [95%CI]
% brain volume loss /
year (SIENA)
- -0.48 [-0.70 –-0.25],
p<0.001








0.2 [-3.1–3.5], p = 0.9 39.6 [36.0–
43.2]


















MD (×10−3 mm2/s) 0.87 [0.83–
0.91]
0.0026 [-0.0041–




0.0073], p = 0.9
0.012 [-0.0085–
0.032], p = 0.2
-0.0023 [-0.012–
0.0073], p = 0.6
L1 (×10−3 mm2/s) 1.2 [1.2–1.3] 0.00064 [-0.0079–
0.0092], p = 0.9
1.3 [1.2–1.3] -0.00062 [-0.0095–
0.0082], p = 0.8
0.017 [-0.0018–
0.036], p = 0.08
-0.0012 [-0.013–
0.011], p = 0.8
RD (×10−3 mm2/s) 0.68 [0.64–
0.71]
0.0036 [-0.0026–




0.0071], p = 0.8
0.0093 [-0.013–
0.032], p = 0.4
-0.0028 [-0.011–
0.0060], p = 0.5
Relative motion (mm) 0.46 [0.43–
0.49]
0.0073 [-0.018–









GM = Grey matter, DTI = Diffusion Tensor Imaging, FA = Fractional Anisotropy, MD = Mean Diffusivity, L1 = axial diffusivity, RD = radial diffusivity,
PD = Parkinson’s disease.
doi:10.1371/journal.pone.0143923.t003
Fig 1. Percentage change in brain metrics over one year. (A) Total brain volume change (%) per year via SIENA, (B) percent FA change per year, and (C)
grey matter CBF change per year (%). (A) shows a significant main effect of time in each group whereas (B) and (C) show no significant change; there were
no significant group-by-time interactions in upon total brain volume, FA, or CBF change (see Table 3). Note, the y-axis scale increases from [–3 3] in (A), to [–
6 6] in (B), to [–35 35] in (C).
doi:10.1371/journal.pone.0143923.g001
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gyrus (temporo-occipital region) and left orbito-frontal cortex (Fig 3). When performing vox-
elwise analysis of DTI metrics along principal white matter tracts using TBSS, there were no
significant differences between controls and our sample of PD participants in the rate of change
of DTI metrics; there were no voxelwise differences in the rate of perfusion change.
Fig 2. Significant MRI change over time across both groups. (A) Blue indicates significant grey matter atrophy over one year. (B-E) depict results derived
from TBSS; the FA skeleton is shown in green, while red indicates significant change over time. (B) Significant reduction in FA over time in multiple white
matter tracts. Significant increases in MD (C), L1 (D), and RD (E) over time. MD and L1 showed localized increases in right superior corona radiata. The
pattern of increases in RD over time mirrored the regions identified in the FA comparison. All comparisons p<0.05 corrected for multiple comparisons using
threshold free cluster enhancement, displayed in radiological convention (right of image is left of brain). Slices displayed: z = -18, -8, 0, 22, 32, 42 mm.
doi:10.1371/journal.pone.0143923.g002
One Year MRI Follow Up in PD
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Discussion
This longitudinal multimodal MRI study investigated progressive changes in a group of older
Parkinson’s disease patients with moderate disease burden over one year using structural, dif-
fusion, and perfusion MRI. A voxelwise analysis of structural MRI, but not DTI (via TBSS) or
perfusion MRI, revealed significantly greater change in PD relative to matched healthy controls
over time. The areas of significantly grey matter atrophy in PD were localized to bilateral infe-
rior and right middle temporal cortex, and left orbito-frontal cortex, consistent with areas of
faster cortical thinning reported in PD-MCI [21]. Furthermore, these areas have been associ-
ated with more advanced stages of PD [4, 39–41]. However, reports of cerebral tissue loss over
time in non-demented PD range from no statistical difference from normal aging [14, 15, 18,
24], to both global and regionally accelerated atrophy in PD [12, 21, 22]. These varying results
likely reflect the use of different methodologies, advancement of imaging and processing tech-
niques, length of follow up, and heterogeneity of age and disease severity within PD.
Longitudinal DTI changes in the context of PD are virtually unexplored. Similar to the cur-
rent study, Rossi et al. [42] failed to identify significant DTI change over two years in PD using
TBSS. However, Ofori et al. [24] recently identified longitudinal changes in free-water within
the substantia nigra in PD over one year, and these changes predicted longitudinal change in
both motor and cognitive outcomes. The differing results may be explained through methodol-
ogy as well as the composition of the PD groups studied. The current study and Rossi et al.
acquired a low number of diffusion encoding directions (28 and 20, respectively) and employed
standard DTI processing to investigate voxelwise differences along the centers of principal
white matter tracts using TBSS. Ofori et al., [24] on the other hand, acquired a larger number
(64) of diffusion directions and employed a more advanced bi-tensor diffusion model, which
allows modeling of free water as well as water molecules close to tissue membranes, resulting in
FA and MD of tissue compartments, as well as a free-water compartment. Perhaps more rele-
vant, Ofori et al. [24] utilized a region of interest approach focused on an area known to be
involved in PD, the substantia nigra, while the current study and Rossi et al.[42] used a whole-
brain, hypothesis-free, voxelwise approach. In addition, our sample of PD participants were
older and of moderate disease severity, whereas those investigated by Ofori et al. were younger
with shorter disease duration. When investigated using traditional DTI models and TBSS in
the current study, older PD patients and matched controls exhibited similar rates of DTI
change over time, suggesting that any PD-specific changes over one year on this measure does
not extend beyond the normal age-associated change. However, future work may benefit by
adopting the approach used by Ofori and colleagues; it will be particularly pertinent to
Fig 3. Accelerated atrophy in PD. Blue-green indicates areas where PD showed a higher rate of GM atrophy than controls over one year, overlaid on the
MNI152_T1_brain image (slices displayed: z = -18, -14, 0, 12 mm; TFCE-corrected p<0.05; radiological convention).
doi:10.1371/journal.pone.0143923.g003
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determine whether the metrics that arise from the bi-tensor diffusion model are able to detect
change in other white matter areas affected by PD progression.
We are unaware of any longitudinal perfusion MRI studies that have tracked PD progres-
sion, but radiotracer-based studies suggest that reduced metabolism and perfusion may occur
early in the disease process [43]. Perfusion reductions have been identified in non-demented
PD relative to controls [44], while converters to PDD exhibited widespread reductions in corti-
cal metabolic activity [45] and perfusion [46] over two years. Huang et al. [47] identified the
differential progression of metabolic (FDG) abnormalities associated with motor and cognitive
aspects in PD. Imaging PD participants at baseline, then two, and four years later, they showed
an increasing expression of a topographic pattern of metabolic activity associated with the
motor aspects of PD significantly increased relative to healthy controls at all three timepoints.
Conversely, an established PD cognitive pattern only diverged from controls at four years after
baseline. Our PD group, although showing regional reductions in perfusion at baseline, under-
went no significant perfusion deterioration over a year and showed no significant difference in
rate of change between PD and controls groups.
Pseudo-continuous ASL has both adequate test-retest [48] and inter-scanner reliability [49].
However, of the three MR modalities used in our study, ASL had the highest variability. There-
fore, our failure to detect perfusion change over time may reflect (a) a small change masked by
the short follow-up period or relatively high inter- and intra-subject variability, (b) no underly-
ing perfusion change, or (c) the susceptibility of perfusion MRI to be influenced by short-term,
state-dependent changes that may mask underlying long term effects, e.g. the effects of eyes
open/closed or drowsiness [50]. While all participants closed their eyes in the present study, we
did not monitor drowsiness or other physiological states while in the scanner. It is therefore
possible that perfusion changes associated with psychological state masked disease-specific
changes of smaller magnitude that may have occurred over one year. This last point may also
explain the counterintuitive finding of structural changes in the absence of more ‘functional’
perfusion or microstructural diffusion changes. While one might expect to identify functional
and microstructural changes prior to the occurrence of gross atrophy, the perfusion and diffu-
sion measures may be more variable, depending on, for example, physiological state or scanner
stability (e.g. field homogeneity). While evidence suggests that early perfusion and metabolic
reductions may lead to subsequent atrophy in PD, atrophy and hypometabolism do not coin-
cide in every single cerebral region; for example in some studies the temporal lobe has shown
more atrophy than hypometabolism [51]. This may reflect a compensatory mechanism capable
of maintaining neuronal activity despite structural damage [51, 52].
Over one year, our PD group remained clinically stable. We measured no significant change
in overall motor severity or cognitive impairment in the group as a whole. It is perhaps unsur-
prising then that the PD group exhibited only localized accelerated brain change. While serial
imaging over one year in Huntington’s disease [10], Alzheimer’s disease [53], and multiple
sclerosis [11] has revealed increased atrophy relative to controls, one year is a brief epoch rela-
tive to the overall duration of PD. Longer follow up periods may be needed to capture divergent
trajectories of progressive brain changes. Furthermore, brain deterioration may accelerate in
tandem with cognitive impairments, and these impairments generally require greater than one
year to manifest in a sample that begins with relatively normal cognition. While cognitive sub-
groups could not be meaningfully explored in our study (four PD-MCI participants and only
one conversion to dementia), recent work has shown areas where cortical thinning occurs
faster in PD-MCI [21] and those developing dementia [19].
While we corrected all voxel-wise imaging tests for multiple comparisons across space, we
did not explicitly correct for the number of imaging measures utilized. Consistency with recent
findings lends support to our results [19, 21], but all group × time interactions disappeared at
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the more stringent statistical threshold of TFCE-corrected p<0.01. While older and at a mod-
erate stage of disease, most PD patients in this sample were cognitively unimpaired at baseline
and only one converted to dementia over the duration of the study (this individual was
excluded from the perfusion analysis due to motion). It is possible that PD patients developing
dementia may exhibit accelerated brain changes, but this could not be tested in the current
study.
All scans were acquired with the same hardware and software versions, bar two baseline
scans (both stable PDN) that were acquired before a software upgrade. We did not account for
this change in software version as it applied to only two individuals. We do not believe that this
small inconsistency would alter conclusions; however this could not meaningfully be tested.
Motion influences are always of concern in MRI investigations. We found no difference in
motion between PD and controls and no difference in the extent of motion between DTI scan-
ning sessions. Even so, relative motion was included as a covariate in all DTI comparisons, as
motion can particularly affect DTI measures [54]. While standard DTI processing steps were
followed, the recent work by Ofori et al.[24] suggests that novel, more robust model fitting and
analysis pipelines should be adopted for further diffusion work.
In conclusion, both older, PD participants with moderate disease and matched controls
showed grey matter atrophy and change in DTI metrics, but not perfusion MRI, over one year.
The PD group showed accelerated grey matter loss in bilateral inferior and right middle tempo-
ral, and left orbito-frontal cortices relative to controls. However, we identified a similar rate of
voxelwise decline across DTI (via TBSS) and no perfusion change. Future studies may benefit
from focusing on those at increased risk of developing dementia (e.g. PD-MCI), employing
novel diffusion acquisitions and models, and following these patients over longer time periods
in order to isolate PD-specific brain patterns of disease and cognitive progression.
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